- Previous Close
0.2990 - Open
0.2900 - Bid 0.2700 x 200
- Ask 0.2900 x 1400
- Day's Range
0.2709 - 0.3099 - 52 Week Range
0.1800 - 52.8000 - Volume
17,811,267 - Avg. Volume
7,349,620 - Market Cap (intraday)
1.978M - Beta (5Y Monthly) 1.86
- PE Ratio (TTM)
0.01 - EPS (TTM)
21.9400 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
seelostherapeutics.comRecent News: SEEL
View MorePerformance Overview: SEEL
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SEEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SEEL
View MoreValuation Measures
Market Cap
2.04M
Enterprise Value
11.91M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
2.80
Financial Highlights
Profitability and Income Statement
Profit Margin
203.13%
Return on Assets (ttm)
-261.11%
Return on Equity (ttm)
--
Revenue (ttm)
2.01M
Net Income Avi to Common (ttm)
4.09M
Diluted EPS (ttm)
21.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
294k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-34.28M
Research Analysis: SEEL
View MoreCompany Insights: SEEL
SEEL does not have Company Insights